Wisconsin Prostate SPORE

Publications

---

[2025]

Rastogi I, Mannone JA, Gibadullin R, Moseman JE, Sidney J, Sette A, McNeel DG, Gellman SH. β-amino acid substitution in the SIINFEKL antigen alters immunological recognition. Cancer Biol Ther. 2025 Dec;26(1):2486141. doi: 10.1080/15384047.2025.2486141. Epub 2025 Apr 8. PMID: 40200635; PMCID: PMC11988276.

Santoro-Fernandes V, Schott B, Weisman AJ, Lokre O, Cho SY, Perlman SB, Perk TG, Jeraj R. Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy. J Nucl Med. 2025 Apr 1;66(4):565-571. doi: 10.2967/jnumed.124.267809. PMID: 39947917.

Hribernik N, Strasek K, Studen A, Zevnik K, Skalic K, Jeraj R, Rebersek M. Early-time-point ¹⁸F-FDG-PET/CT and other prognostic biomarkers of survival in metastatic melanoma patients receiving immunotherapy. Radiol Oncol. 2025 Feb 27;59(1):43-53. doi: 10.2478/raon-2025-0014. PMID: 40014787; PMCID: PMC11867565.

Sharifi MN, Feng E, Rydzewski NR, Taylor AK, Sperger JM, Shi Y, Helzer KT, Bootsma ML, Carreno V, Chang AH, Nunamaker LA, Blitzer GC, Shang TA, Subramanian A, Bjartell A, Josefsson A, Wikström P, Feng E, Kohli M, Yang R, Dehm SM, Small EJ, Aggarwal R, Quigley DA, Lang JM, Zhao SG, Sjöström M. Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer. Mol Oncol. 2025 Feb 22. doi: 10.1002/1878-0261.70001. Epub ahead of print. PMID: 39985777.

Dal Pra A, Ghadjar P, Ryu HM, Proudfoot JA, Hayoz S, Michalski JM, Spratt DE, Liu Y, Schär C, Berlin AM, Zwahlen DR, Simko JP, Hölscher T, Efstathiou JA, Polat B, Sandler HM, Hildebrandt G, Parliament MB, Mueller AC, Dayes IS, Plasswilm L, Correa RJM, Robertson JM, Karrison TG, Davicioni E, Hall WA, Feng FY, Pollack A, Thalmann GN, Nguyen PL, Aebersold DM, Tran PT, Zhao SG. Predicting dose response to prostate cancer radiotherapy: validation of a radiation signature in the randomized phase III NRG/RTOG 0126 and SAKK 09/10 trials. Ann Oncol. 2025 May;36(5):572-582. doi: 10.1016/j.annonc.2025.01.017. Epub 2025 Feb 13. PMID: 39986927; PMCID: PMC12034480.

Sharifi MN, Sperger JM, Taylor AK, Tippins KE, Reese SR, Carreno V, Kaufmann KR, Chang AH, Nunamaker LA, Linebarger C, Mora-Rodriguez L, Schehr JL, Krause HM, Helzer KT, Bootsma ML, Blitzer GC, Floberg JM, Kyriakopoulos CE, Emamekhoo H, Heath EI, Wells M, Tagawa ST, Sjöström M, Choudhury AD, Yu M, Armstrong AJ, Rathkopf DE, Beltran H, Nelson PS, Feng FY, Dehm SM, Kosoff D, Wei XX, McKay RR, Zhao SG, Lang JM. High-purity CTC RNA sequencing identifies prostate cancer lineage phenotypes prognostic for clinical outcomes. Cancer Discov. 2025 Feb 6. doi: 10.1158/2159-8290.CD-24-1509. Epub ahead of print. PMID: 39912912.

[2024]

Jeon D, Hill E, McNeel DG. Toll-like receptor agonists as cancer vaccine adjuvants. Hum Vaccin Immunother. 2024 Dec 31;20(1):2297453. doi: 10.1080/21645515.2023.2297453. Epub 2023 Dec 28. PMID: 38155525; PMCID: PMC10760790.

Tonelli TP, Eickhoff JC, Johnson LE, Liu G, McNeel DG. Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer. Hum Vaccin Immunother. 2024 Dec 31;20(1):2395680. doi: 10.1080/21645515.2024.2395680. Epub 2024 Aug 29. PMID: 39208856; PMCID: PMC11364063.

Lokre O, Perk TG, Weisman AJ, Govindan RM, Chen S, Chen M, Eickhoff J, Liu G, Jeraj R. Quantitative evaluation of lesion response heterogeneity for superior prognostication of clinical outcome. Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3505-3517. doi: 10.1007/s00259-024-06764-0. Epub 2024 May 31. PMID: 38819668; PMCID: PMC11445285.

Hribernik N, Strasek K, Huff DT, Studen A, Zevnik K, Skalic K, Jeraj R, Rebersek M. Role of quantitative imaging biomarkers in an early FDG-PET/CT for detection of immune-related adverse events in melanoma patients: a prospective study. Radiol Oncol. 2024 Sep 15;58(3):335-347. doi: 10.2478/raon-2024-0045. PMID: 39287171; PMCID: PMC11406908.

Muralidhar A, Gamat-Huber M, Vakkalanka S, McNeel DG. Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy. J Immunother Cancer. 2024 May 20;12(5):e008848. doi: 10.1136/jitc-2024-008848. PMID: 38772685; PMCID: PMC11110578.

Jeon D, Hill E, Moseman JE, McNeel DG. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy. J Immunother Cancer. 2024 May 3;12(5):e008799. doi: 10.1136/jitc-2024-008799. PMID: 38702146; PMCID: PMC11086196.

Zhang H, Mañán-Mejías PM, Miles HN, Putnam AA, MacGillivray LR, Ricke WA. DDX3X and Stress Granules: Emerging Players in Cancer and Drug Resistance. Cancers (Basel). 2024 Mar 12;16(6):1131. doi: 10.3390/cancers16061131. PMID: 38539466; PMCID: PMC10968774.

Invited Presentations

---

[2025]

• [April] – Glenn Liu presented his SPORE research (“Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC”) at the 2025 AACR Annual Meeting in Chicago.

• [March] – Dave Jarrard gave a keynote address, “Manipulating the androgen axis and new targets in oligometastatic prostate cancer” at the international meeting of the Korean Prostate Society in Seoul.

 

In the News

---

[2025]

SPORE leaders awarded $600k Wisconsin Partnership Program grant to investigate biological contributors to aggressive cancer and treatment resistance

This three-year project aims to address disparities in cancer outcomes by investigating the biology of cancers and the factors that contribute to aggressive cancers or lead to the development of treatment resistance. The research team, led by Dr. Joshua Lang (with Co-Investigators Dr. Earlise Ward and Dr. George Zhao) will introduce a minimally invasive liquid biopsy testing approach, which is essentially a blood draw, and utilize a new type of testing called fragmentomics to gather more information about a patient’s tumor and patterns of potential treatment resistance or cancer recurrence.

Read more

---

Dr. Steve Cho treats advanced metastatic prostate cancer with theranostics, featured in Advances

SPORE Research Core Co-Director Steve Cho, MD, treats prostate cancer patients with two approved theranostic drugs and is researching how to calculate precision doses of those tailored to each patients’ needs. Learn more about Dr. Cho’s exciting work in the January 2025 issue of the Carbone Cancer Center’s external newsletter.

Read article

---

[2024]

SPORE investigators profiled on Fox47 News in campaign highlighting prostate cancer research at Carbone Cancer Center

Prostate cancer affects men all over the world, and cutting-edge research and clinical trials are happening right here in Madison. As part of Fox47’s effort to raise awareness and money to battle the disease during the month of “No Shave November,” the local news station is featuring interviews with SPORE researchers about challenges, successes, and innovations in their work on prostate cancer at UW-Madison.

Interview with Dr. Jarrard (11/6/24)

Interview with Dr. Lang (11/13/24)

Interview about Lang Lab Clinical Trial (11/20/24)

Interview with Dr. McNeel (11/27/24)

---

[2023]

UW Carbone Cancer Center receives SPORE designation, federal grant to support prostate cancer research

University of Wisconsin Carbone Cancer Center will be designated as a Specialized Program of Research Excellence, or SPORE, by the National Cancer Institute (NCI) for research initiatives to advance new prostate cancer treatments.

This highly competitive designation comes with more than $11 million in federal funding to support new and existing research efforts, according to Dr. David Jarrard, surgical oncologist and deputy director at UW Carbone, and professor of urology at University of Wisconsin School of Medicine and Public Health.

Read announcement